Featured

 Global Hib vaccination: reasons to cheer and fear

Conjugate Haemophilus influenzae type b (Hib) vaccination is one of the major global health achievements of the past three or four decades. H influenzae type b is a key cause of disease and death in unvaccinated populations, and that burden falls most severely on young children.

 How a Childhood Vaccine Reduces Risk of a Cancer

Young children are routinely vaccinated against Haemophilus influenzae Type B, or HiB, a bacterium that can cause meningitis and other serious problems. But the HiB vaccine has an added benefit: It reduces the risk for acute lymphoblastic leukemia, or ALL, the most common childhood cancer, and now scientists know why.

Articles of Interest

Five-in-One Vaccine Carries Small Risk of Seizure

Parents should not be concerned, experts say, as the overall risk is very low and there was no increased risk of seizures recurring or other lasting ill effects

Hib Vaccine: What You Need to Know

Before Hib vaccine, Hib disease was the leading cause of bacterial meningitis among children under 5 years old in the United States.

Resources

CDC

Children over 5 years old and adults usually do not need Hib vaccine. But it may be recommended for older children or adults with asplenia or sickle cell disease, before surgery to remove the spleen, or following a bone marrow transplant. It may also be recommended for people 5 to 18 years old with HIV.

Patient.info

The introduction of the Hib conjugate vaccine in the UK has resulted in more than 90% reduction in the incidence of invasive Hib disease. The clinical efficacy of the conjugate Hib vaccines is estimated as 83-100%. The vaccination also reduces nasopharyngeal carriage in asymptomatic carriers and therefore confers herd immunity to unvaccinated children.